Strides Pharma (STAR) | Stock Overview & Key Data
Strides Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,675.00 on October 14, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Strides Pharma
STAR
|
98.28B Mid-cap | 7.91% | -5.93% | 21.68% | 24.92% | 19.09% | 19.61% | 162.17% | 36.49% | 3.15% | 222.14% | 318.10% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | 1.12% | -4.39% | 20.53% | -2.62% | -1.58% | -18.17% | 77.37% | -2.17% | -2.17% | -2.17% | -2.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | 0.54% | 2.81% | 39.46% | 3.75% | 13.25% | 30.36% | 489.12% | 756.32% | 2,077.38% | 16,439.72% | 20,028.75% |
Ownership & Short Interest
Calculate Your Strides Pharma Investment Returns
Long-Term Investment Performance Analysis
Strides Pharma stock price in Jul 2016 was ₹1,090.09, A ₹1,000.00 lump sum investment in Strides Pharma made 9 years ago would be worth approximately ₹995.61 today, representing a negative return of -0.44%. This translates to an annualized return (CAGR) of -0.04%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is STAR's 52-week high and low?
- In the last 52 weeks, Strides Pharma reached a high of ₹1,231.00 (on May 12, 2026) and a low of ₹768.65 (on January 29, 2026).
- What is the market cap and P/E ratio for STAR?
- Curious about Strides Pharma's size and valuation? Its market capitalization stands at 98.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.26, and the forward P/E (looking ahead) is 14.73.
- Does STAR pay dividends? If so, what's the yield?
- Yes, Strides Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.74%, and the company has paid an average of ₹2.67 per share annually over the past 3 years.
- Who are Strides Pharma's main competitors or similar companies to consider before investing?
When looking at Strides Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -18.17% 77.37% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -21.75% 112.96% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 30.36% 489.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Strides Pharma Science Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Strides Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 138.93%, the Debt to Equity ratio from the most recent quarter is 65.79, and its Gross Profit Margin stands at 61.25%.
- What is the recent revenue and earnings growth for STAR?
- Looking at Strides Pharma's growth, its revenue over the trailing twelve months (TTM) was INR47B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.60%, and quarterly earnings saw a YoY growth of 129.80%.
- How much of STAR stock is held by insiders and institutions?
- Wondering who owns Strides Pharma stock? Company insiders (like executives and directors) hold about 30.78% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 26.99%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.